• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接种 COVID-19 疫苗后发生带状疱疹性眼病:偶发还是更多?

Herpes Zoster Ophthalmicus After COVID-19 Vaccination: Chance Occurrence or More?

机构信息

Department of Ophthalmology, Government Medical College and Hospital, Chandigarh, India.

出版信息

Cornea. 2022 Feb 1;41(2):254-256. doi: 10.1097/ICO.0000000000002881.

DOI:10.1097/ICO.0000000000002881
PMID:34690265
Abstract

As the understanding of COVID-19 infection becomes better, it is being recognized as a complex multisystem pathology rather than just affecting the lungs. Several ocular findings have been documented by researchers in individuals infected with COVID-19, and ocular symptoms may even be the first presenting feature of COVID-19 infection in 2.26% individuals. Several countries have started vaccination with inactivated or live vaccines to combat this pandemic, and varied side effects have been reported after vaccination. Few cases of herpes zoster have previously been reported in elderly patients with comorbidities after receiving COVID-19 vaccines. In this article, the authors described 2 interesting cases of herpes zoster ophthalmicus (HZO) after receiving a live COVID-19 vaccine. The first case was a 35-year-old immunocompetent man who developed HZO 3 days postvaccine. The second case was a 40-year-old immunocompetent man who developed HZO 28 days postvaccine. To the best of our knowledge, no literature to date has described HZO after live vaccine.

摘要

随着对 COVID-19 感染的认识不断加深,人们逐渐认识到它是一种复杂的多系统疾病,而不仅仅影响肺部。研究人员已经在感染 COVID-19 的个体中记录了几种眼部发现,并且眼部症状甚至可能是 COVID-19 感染的首发症状,占 2.26%。为了应对这一流行病,一些国家已经开始使用灭活或活疫苗进行接种,但接种后报告了各种副作用。此前,在接受 COVID-19 疫苗接种后,患有合并症的老年患者中曾有少数带状疱疹病例报告。在本文中,作者描述了 2 例接种活 COVID-19 疫苗后发生的带状疱疹性眼病(HZO)的有趣病例。第一例是一名 35 岁免疫功能正常的男性,在接种疫苗后 3 天发生 HZO。第二例是一名 40 岁免疫功能正常的男性,在接种疫苗后 28 天发生 HZO。据我们所知,迄今为止尚无文献描述活疫苗接种后发生 HZO。

相似文献

1
Herpes Zoster Ophthalmicus After COVID-19 Vaccination: Chance Occurrence or More?接种 COVID-19 疫苗后发生带状疱疹性眼病:偶发还是更多?
Cornea. 2022 Feb 1;41(2):254-256. doi: 10.1097/ICO.0000000000002881.
2
Presumed Herpes Zoster Ophthalmicus Reactivation Following Recombinant Zoster Vaccination.疑似带状疱疹眼炎在带状疱疹重组疫苗接种后的再激活。
Cornea. 2021 Feb 1;40(2):248-250. doi: 10.1097/ICO.0000000000002537.
3
A Case Report of Herpes Zoster Ophthalmicus and Meningitis After COVID-19 Vaccination.接种 COVID-19 疫苗后发生带状疱疹性眼病和脑膜炎的病例报告。
J Korean Med Sci. 2022 May 23;37(20):e165. doi: 10.3346/jkms.2022.37.e165.
4
[Herpes Zoster Ophthalmicus after Pfizer BNT162b2 and Moderna mRNA-1273 vaccination in two young and immunocompetent patients].两例年轻且免疫功能正常患者接种辉瑞BNT162b2和莫德纳mRNA-1273疫苗后发生的眼部带状疱疹
J Fr Ophtalmol. 2022 Nov;45(9):1000-1003. doi: 10.1016/j.jfo.2022.09.004. Epub 2022 Sep 23.
5
Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus.伐昔洛韦与阿昔洛韦治疗眼部带状疱疹的疗效及安全性比较。
Ophthalmology. 2000 Aug;107(8):1507-11. doi: 10.1016/s0161-6420(00)00222-0.
6
Prevalence of Ocular Manifestations and Visual Outcomes in Patients With Herpes Zoster Ophthalmicus.眼部带状疱疹患者眼部表现及视觉预后的患病率
Cornea. 2017 Mar;36(3):338-342. doi: 10.1097/ICO.0000000000001046.
7
Herpetic Eye Disease After SARS-CoV-2 Vaccination: A CDC-VAERS Database Analysis.接种 SARS-CoV-2 疫苗后的疱疹性眼病:CDC-VAERS 数据库分析。
Cornea. 2023 Jun 1;42(6):731-738. doi: 10.1097/ICO.0000000000003246. Epub 2023 Jan 25.
8
Herpetic Eye Disease Following the SARS-CoV-2 Vaccinations.接种 SARS-CoV-2 疫苗后的疱疹性眼病。
Ocul Immunol Inflamm. 2023 Aug;31(6):1151-1162. doi: 10.1080/09273948.2022.2103831. Epub 2022 Aug 1.
9
Varicella Zoster Reactivation Causing Acute Retinal Necrosis following mRNA COVID-19 Vaccination in a Young Immunocompetent Man.一名年轻免疫功能正常男性在接种mRNA新冠疫苗后,水痘带状疱疹病毒再激活导致急性视网膜坏死
Ocul Immunol Inflamm. 2023 Apr;31(3):609-612. doi: 10.1080/09273948.2022.2033795. Epub 2022 Feb 8.
10
Valacyclovir versus acyclovir for the treatment of herpes zoster ophthalmicus in immunocompetent patients.伐昔洛韦与阿昔洛韦治疗免疫功能正常患者的眼部带状疱疹
Cochrane Database Syst Rev. 2016 Nov 14;11(11):CD011503. doi: 10.1002/14651858.CD011503.pub2.

引用本文的文献

1
Herpes zoster ophthalmicus temporally after COVID-19 vaccination: a systematic review of uncontrolled case reports and case series.新冠病毒疫苗接种后颞侧眼部带状疱疹:对非对照病例报告和病例系列的系统评价
Proc (Bayl Univ Med Cent). 2024 Dec 6;38(1):69-75. doi: 10.1080/08998280.2024.2426439. eCollection 2025.
2
Corneal nerve fiber morphology following COVID-19 infection in vaccinated and non-vaccinated population.接种疫苗和未接种疫苗人群中 COVID-19 感染后的角膜神经纤维形态。
Sci Rep. 2024 Jul 22;14(1):16801. doi: 10.1038/s41598-024-67967-x.
3
Herpes Zoster and COVID-19 Vaccination: A Narrative Review.
带状疱疹与新冠病毒疫苗接种:一篇叙述性综述
Clin Cosmet Investig Dermatol. 2023 Nov 16;16:3323-3331. doi: 10.2147/CCID.S441898. eCollection 2023.
4
Corneal Adverse Events Associated with SARS-CoV-2/COVID-19 Vaccination: A Systematic Review.与SARS-CoV-2/COVID-19疫苗接种相关的角膜不良事件:一项系统评价
Vaccines (Basel). 2023 Jan 12;11(1):166. doi: 10.3390/vaccines11010166.
5
Corneal Complications after COVID-19 Vaccination: A Systemic Review.新冠疫苗接种后的角膜并发症:一项系统综述
J Clin Med. 2022 Nov 18;11(22):6828. doi: 10.3390/jcm11226828.
6
Varicella-Zoster virus reactivation following severe acute respiratory syndrome coronavirus 2 vaccination or infection: New insights.接种或感染严重急性呼吸综合征冠状病毒 2 后水痘带状疱疹病毒再激活:新的见解。
Eur J Intern Med. 2022 Oct;104:73-79. doi: 10.1016/j.ejim.2022.07.022. Epub 2022 Aug 1.
7
A Case Report of Herpes Zoster Ophthalmicus and Meningitis After COVID-19 Vaccination.接种 COVID-19 疫苗后发生带状疱疹性眼病和脑膜炎的病例报告。
J Korean Med Sci. 2022 May 23;37(20):e165. doi: 10.3346/jkms.2022.37.e165.
8
Potential risk factors for Varicella-zoster virus reactivation after COVID-19 vaccination.新冠病毒疫苗接种后水痘-带状疱疹病毒再激活的潜在风险因素。
J Cosmet Dermatol. 2022 Apr;21(4):1347-1349. doi: 10.1111/jocd.14871. Epub 2022 Feb 25.